Good AM rock n roll fans. today I have a tasty treat for you CBLI. There is a whole lot going on with this company from stem cell lines to being able to stop the russian radiation poison they have been throwing around. Today watch for any volume accumulation mid day due to:
Michael Fonstein, Ph.D., President and Chief Executive Officer at Cleveland BioLabs, will give a presentation on the Company followed by a question and answer session on February 14, at 11:15 a.m. ET.
Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is a small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has initiated a Phase II trial with CBLC102 in hormone refractory prostate cancer.
The Company's other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from apoptosis. CBLB502 is the first compound of its kind to provide protection from both gastrointestinal and hematopoietic (bone marrow/blood production) radiation-induced damage. Other applications for this technology include protection from cancer treatment side effects.
Cleveland BioLabs recently announced a new discovery regarding its Protectan 600 series of compounds being developed for radiation protection. A single administration of CBLB612, the lead compound in the Protectans 600 series, in healthy mice resulted in a three-fold increase in the number of progenitor (originator) stem cells in mouse bone marrow within 24 hours after administration. Moreover, the number of these stem cells in peripheral blood was increased 10-fold within four days of administration.
Dr. Fonstein will be available for investor meetings in New York on February 13-14.
11:15 Q & A> if a nice rally develops in the stock today I imagine it will be just after lunch. ~ stoney
Michael Fonstein, Ph.D., President and Chief Executive Officer at Cleveland BioLabs, will give a presentation on the Company followed by a question and answer session on February 14, at 11:15 a.m. ET.
Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is a small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has initiated a Phase II trial with CBLC102 in hormone refractory prostate cancer.
The Company's other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from apoptosis. CBLB502 is the first compound of its kind to provide protection from both gastrointestinal and hematopoietic (bone marrow/blood production) radiation-induced damage. Other applications for this technology include protection from cancer treatment side effects.
Cleveland BioLabs recently announced a new discovery regarding its Protectan 600 series of compounds being developed for radiation protection. A single administration of CBLB612, the lead compound in the Protectans 600 series, in healthy mice resulted in a three-fold increase in the number of progenitor (originator) stem cells in mouse bone marrow within 24 hours after administration. Moreover, the number of these stem cells in peripheral blood was increased 10-fold within four days of administration.
Dr. Fonstein will be available for investor meetings in New York on February 13-14.
11:15 Q & A> if a nice rally develops in the stock today I imagine it will be just after lunch. ~ stoney
